,i  #aaf? ,,congress  #a/ ,session  ,h4 
,r4 #caii  ,,9 ,,! ,,h\se ,,(           
,,repres5tatives  ,june #aa1 #bjai,mr4  
,jeffries 7= himself1 ,mr4 ,coll9s (    
,georgia1 ,ms4 ,muc>sel-,p[ell1 & ,mr4  
,cl9e7 introduc$ ! foll[+ bill2 :i* 0   
ref]r$ to ! ,committee on ! ,judici>y   
,a ,,bill  ,to am5d title #ce1 ,unit$   
,/ates ,code1 to prev5t d\ble pat5t+1 & 
= o!r purposes4  #a4 ,%ort title ,?is   
,act may be cit$ z ! ,t]m9at+ !         
,ext5sion ( ,rights ,misappropriat$ ,act
 ( #bjai or ! ,t]m ,act ( #bjai4  #b4   
,prev5tion ( d\ble pat5t+  7a7 ,9 g5]al 
,section #bec ( title #ce1 ,unit$ ,/ates
 ,code1 is am5d$ by add+ at ! end !     
foll[+3  7c7 ,disclaim]s ( drug pat5t   
t]m  7#a7 ,9 g5]al ,except z provid$ 9  
p>agraph 7#b71 9 a proce$+ *all5g+ !    
validity ( pat5ts "u section #eje7;c7 ( 
! ,f$]al ,food1 ,drug1 & ,cosmetic ,act 
7#ba ,u4,s4,c4 #cee7;c77 ) respect to a 
drug1 "u section #cea7l7 ( ! ,public    
,heal? ,s]vice ,act 7#db ,u4,s4,c4      
#bfb7l77 ) respect to a biological      

product1 or a ,f$]al di/rict c\rt       
proce$+ involv+ pat5ts t are ! subject (
 an action "u section #bga7;e77#b71 !   
pat5tee %all be presum$ to h disclaim$ !
 pat5t t]m = ea* ( ! li/$ pat5ts aft] ! 
date on :i* ! t]m ( ! fir/ pat5t        
expires1 subject to ! exceptions provid$
 = 9 subsection 7#b74  7#b7             
,demon/ration ( di/9ct inv5tions ,if a  
pat5tee demon/rates by a prepond]ance ( 
! evid5ce t c]ta9 pat5ts describ$ 9     
p>agraph 7#a7 cov] pat5tably di/9ct     
inv5tions f ! inv5tion claim$ 9 ! fir/  
su* pat5t to expire1 no "p ( ! t]m ( any
 su* pat5t %all be presum$ to h be5     
disclaim$1 & all pat5t t]m ext5sions    
grant$ by ! ,unit$ ,/ates ,pat5t &      
,tradem>k ,(fice %all be respect$1      
unless & to ! ext5t ! pat5tee expressly 
disclaims1 9 writ+1 ! pat5t t]m = ea*   
su* pat5t4  4  7b7 ,,uspto review  7#a7 
,def9itions ,9 ?is subsection-- 7,a7 !  
t]m ,(fice means ! ,unit$ ,/ates ,pat5t 
& ,tradem>k ,(fice2 &  7,b7 ! t]m       
,director means ! ,"u ,secret>y (       

,comm]ce = ,intellectual ,prop]ty &     
,director ( ! ,(fice4  7#b7 ,review ,!  
,director %all conduct a compreh5sive   
review ( ! pat5t exam9ation proc$ures ( 
! ,(fice to det]m9e :e!r ! ,(fice--     
7,a7 is us+ be/ exam9ation practices1   
guidance1 & proc$ures to avoid !        
issuance ( pat5ts relat+ to ! same drug1
 or biological product1 t are n         
pat5tably di/9ct f "o ano!r1 & n subject
 to an appropriate disclaim] ( pat5t    
t]m2 &  7,b7 %\ld develop & implem5t new
 practices1 guidance1 or proc$ures to-- 
7i7 improve exam9ation ( pat5t          
applications relat+ to ! same drug or   
biological product2 &  7ii7 r$uce !     
improp] issuance ( pat5ts t improp]ly   
ext5d ! t]m ( exclusivity af=d$ a new   
drug or biological product4  7#c7       
,report ,n lat] ?an #a ye> aft] ! date (
 enactm5t ( ?is ,act1 ! ,director %all  
submit to ! ,committee on ! ,judici>y ( 
! ,h\se ( ,repres5tatives a report t    
conta9s--  7,a7 ! f9d+s f ! review      
conduct$ "u p>agraph 7#b72 &  7,b7 any  

recomm5dations ( ! ,director ) respect  
to ! review conduct$ "u p>agraph 7#b74